April 4, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares over potential securities laws violations in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Portola Pharmaceuticals Inc (NASDAQ:PTLA) concerning whether certain statements regarding by Portola Pharmaceuticals business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) grew from $20.09 per share in May 2014 to as high as $49.77 per share in September 2015.

On February 26, 2016, Portola Pharmaceuticals Inc reported its fourth quarter and year end 2015 financial results and provided a corporate update. Portola Pharmaceuticals Inc reported that its annual total Revenue rose from $9.62 million in 2014 to $12.07 million in 2015, while its Net Loss increased from $137.12 million in 2014 to $226.50 million in 2015.

On March 24, 2016 Portola Pharmaceuticals Inc announced data from the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study, which evaluated the superiority of extended-duration anticoagulation with oral betrixaban compared with standard of care anticoagulation with injectable enoxaparin for the prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients.

Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) declined to as low as $18.20 per share on March 28, 2016.